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Askin’s tumor is a primitive neuroectodermal tumor developing from the soft tissues of the chest wall. Its diagnosis
approach is complex and requires a multidisciplinary team. Given the rarity of this entity, no regimen has been
validated in the literature. We report two cases of Askin’s tumor with a major response to polychemotherapy and
surgical resection in one case. These cases show that treatment of Askin’s tumor should be multimodal, requiring
discussion in multidisciplinary tumor working groups.Background
Ewing sarcoma and peripheral primitive neuroectodermal
tumor (previously called peripheral neuroepithelioma)
were originally described in the early 1900s as distinct
clinicopathologic entities. They are rare malignant small
round cell tumors that arise from the primitive nerve cells
of the nervous system, but they can also occur outside the
central nervous system in the chest wall, pelvis and ex-
tremities. Askin’s tumor is a primitive neuroectodermal
tumor (PNET) of the thoracopulmonary region described
the first time in 1979 by Askin et al. about 20 white chil-
dren and adolescents [1]. It develops from the soft tissues
of the chest wall, particularly in the paravertebral region.
Askin’s tumor occurs in young Caucasian adults and is
associated with poor prognosis. Given the rarity of this
recent disease, no regimen has been validated in the litera-
ture. We report two cases of Askin’s tumor with a major
response to polychemotherapy and review different data
about diagnosis and treatment of this entity.
Cases presentation
Case 1
A 17-year-old female presented two months’ history of
cough, weight loss and pain in the right side of the chest.
Physical examination revealed decreased breath sound in
the right lung without any other abnormality. Laboratory
investigations were normal. A chest radiograph showed an
opacity in the right hemithorax with partial destruction of
the sixth rib. To well document this opacity, a computed* Correspondence: zineb247@hotmail.com
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distribution, and reproduction in any mediumtomography (CT) scan was justified. The CT scan revealed
a large lobulated mass on the right lower rib cage develo-
ping from the outside of parenchyma with erosion of the
sixth rib (Figure 1). A CT-guided biopsy showed a malig-
nant, lobular tumor with characteristic Homer Wright
rosettes. A diagnosis of PNET of the chest wall (Askin
Rosai tumor) was made. An isotope bone scan confirmed
that no other skeletal site was involved (Figure 2). The
tumor was classified as T1N0M0. The patient received
four cycles of induction chemotherapy including ifosfa-
mide, vincristine, and adriamycin. She then reported
marked improvement in chest pain. A repeat CT scan
showed disappearance of the chest tumor with residual
erosion of the sixth rib. She was a candidate for surgical
resection. However, she refused the intervention. To date,
she remains disease-free after 10 months of follow-up.
Case 2
A 27-year-old female was admitted for cough, dyspnea,
pain in the right chest and weight loss. Physical exami-
nation showed a 5 × 5 cm rounded fixed mass on the
right chest wall. Laboratory examinations were within
normal limits. A chest radiograph and chest CT scan
showed a soft-tissue density mass in the right rib cage
with partial destruction of the fifth and sixth ribs and
pleural effusion. No mediastinal or axillary lymphaden-
opathy was found. Pleural biopsy revealed a small cell
tumor which stained negative for glycogen but immuno-
cytochemically positive for neuron-specific enolase
(NSE) and CD99. T (11;22) research has not been car-
ried out. The diagnosis of Askin’s tumor was made. An
abdominal CT scan did not show any metastatic
localization. An isotope bone scan confirmed that notral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Large mass on the right lower rib cage developing
from the outside of parenchyma.
Figure 2 Bone scan showing a hyperfixation of the sixth rib.
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as T2N0M0. After four cycles of chemotherapy of doxo-
rubicin and cyclophosphamide, we observed a major
clinical and radiological regression of the soft tissue
mass. The primary tumor was resected, including the
fifth and sixth ribs. Histology revealed residual micro-
scopic tumor compatible with primitive neuroectoder-
mal tumor. The patient received six courses of adjuvant
chemotherapy. To date, she remains disease-free, with
no evidence of recurrence after three years of follow-up.
Discussion
Ewing sarcoma (ES) and peripheral primitive neuroecto-
dermal tumor (PNET) were originally described as dis-
tinct clinicopathologic entities: in 1918, Stout described
a tumor of the ulnar nerve composed of small round
cells focally arranged as rosettes; this entity was subse-
quently designated neuroepithelioma, and then PNET
[2]. Later, in 1921, ES was described as an undifferentia-
ted tumor involving the diaphysis of long bones. It was
also reported to arise in soft tissue (extraosseous ES) [3].
Nevertheless, it has become clear, over the last three
decades, that these entities comprise the same spectrum
of neoplastic diseases known as the Ewing sarcoma fami-
ly of tumors (EFT), which also includes malignant small
cell tumor of the chest wall and atypical ES. ES of the
chest wall were originally reported by Askin et al. in
1979 in 20 white children and adolescents (average age,
14 years) [1]. Since then, PNETs within the thoracopul-
monary region have been termed Askin tumors. This is a
rare disease in the pediatric group, and even rarer in
adults. Caucasian ethnic group is clearly predominant [4].
It is presented as a painful wall mass, often associated with
dyspnea, cough, weight loss, Horner’s syndrome, or re-
gional lymphadenopathy. A chest wall soft-tissue density
mass, sometimes associated with rib erosion and/or pleural
effusion, is the commonest radiographic manifestation [5].
The most important role of the CT scan is to confirm the
presence of a solid chest wall and to demonstrate their
possible intrathoracic extension and/or direct lung inva-
sion [5,6]. Magnetic resonance imaging (MRI) findings of
Askin tumors have been described as heterogeneous soft-
tissue masses with a moderate to high signal intensity on
T1-weighted images, greater than skeletal muscle, and high
signal intensity on T2-weighted images [5,6].
Histological examination shows an undifferentiated
sarcomatous tissue small round cell with scant eosino-
philic cytoplasm, high nuclear/cytoplasmic ratio, small
single nucleoli, and a high mitotic rate. Morphologically,
these features are similar to that of other small round
cell tumors involving bone and soft tissue, including
lymphoma, small cell osteosarcoma, mesenchymal chon-
drosarcoma, dedifferentiated synovial sarcoma, desmo-
plastic small round cell tumors, rhabdomyosarcoma and
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diagnostic problems when examined by light microscopy
alone. Although no routinely used immunohistochemical
stain can positively distinguish EFT from other undifferen-
tiated tumors, the majority of EFT expresses high levels of
a cell surface glycoprotein (designated CD99, MIC2 sur-
face antigen or p30/32MIC2) that is encoded by the CD99
(MIC2X) gene. Another new potential immunohisto-
chemical marker for EFT is NKX2.2, the protein product
of the NKX2-2 gene [7].
Cytogenetic or molecular genetic studies looking for par-
ticular chromosomal translocations t (11; 22) (q24; q12)
and/or their fusion transcripts are usually required to se-
cure the diagnosis [5]. However, it raises the question of its
relationship with ES, which presents a similar transloca-
tion. Marina et al. suggested the following criteria to retain
the diagnostic of Askin’s tumor [8,9]:
 development of the tumor from a peripheral nerve;
 identification of Homer-Wright rosettes;
 expression of NSE and Leu-7;
 existence of cytoplasmic neurosecretory granules
and microtubules
 identification of t (11; 22) (q24; q12);
 detection of proto-oncogenes (N-myc, C-myb,
C-ets-1);
 activity of neurotransmitter biosynthetic enzymes
(tyrosine hydroxylase, dopamine B hydroxylase and
acetylcholine transferase).
Given the rarity and the recent individualization of this
disease, no regimen has been validated in the literature. In
contrast to extraosseous osteogenic sarcomas when ma-
nagement follows the principles established for soft-tissue
tumors rather than primary bone tumors, ES is treated in
the same multidisciplinary manner regardless of whether
it arises in bone or soft tissue. Treatment includes radical
surgical resection, neoadjuvant and adjuvant chemothe-
rapy and radiation [10]. Most clinical centers performing
intensive chemotherapy are reporting long-term survival
rates between 60 and 70%, suggesting that ES is sensitive
to anticancer agents. Current protocols of chemotherapy
are based on a combination of two to six anticancer drugs,
which are continued after locoregional treatment for up to
twelve months [11]. These drugs include doxorubicin,
actinomycin D, cyclophosphamide, ifosfamide, vincristine,
etoposide, busulfan, melphalan and carboplatin. The most
classic associations are: VACA (vincristine, doxorubicin,
cyclophosphamide, actinomycin), VAIA (replacing cyclo-
phosphamide with ifosfamide), EVAIA (addition of etopo-
side to VAIA) and finally VIDE (vincristine, ifosfamide,
doxorubicin, etoposide) [12].
Used radiotherapy doses vary between 50 and 60 Gy. The
prognosis of Askin’s tumor is very poor. Askin reportedthat 14 of 18 patients with known prognosis died four to
forty-four months after diagnosis, and the mean survival
period was eight months [13]. Local recurrences are very
common. Furthermore, metastases are already present at
diagnosis in 10% of cases [14].
Conclusion
In summary, we experienced two cases of Askin’s tumor
with a major response to polychemotherapy. These cases
show that treatment of Askin’s tumor should be multi-
modal. Discussion in multidisciplinary tumor working
groups is indeed warranted.
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